Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BHV 7000

Next Previous
Drug Profile

BHV 7000

Alternative Names: BHV-7000; BPN-25203; KB-3061

Latest Information Update: 24 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Channel Biosciences
  • Developer Biohaven Pharmaceuticals; Biohaven Therapeutics
  • Class Amides; Analgesics; Antidepressants; Antiepileptic drugs; Benzimidazoles; Mood stabilisers; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action KCNQ2 potassium channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Bipolar disorders; Epilepsy; Partial epilepsies
  • Phase II Major depressive disorder
  • Phase I Infantile spasms; Mood disorders; Pain

Most Recent Events

  • 15 Aug 2025 Yale University in collaboration with Biohaven Pharmaceuticals plans a phase I trial for Epilepsy in USA in September 2025 (PO) (NCT07125261)
  • 08 Jun 2025 Biohaven Therapeutics terminates a phase II trial in Bipolar disorders in USA (PO), due to business decision (NCT06423794)
  • 30 Jan 2025 Biohaven Therapeutics completes phase-II/III clinical trials in Bipolar disorders (In adults, In the elderly) in USA (NCT06419582)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top